Poly(ADP‐ribose) Polymerase 1 (PARP1) in Atherosclerosis: From Molecular Mechanisms to Therapeutic Implications

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Medicinal research reviews (Print)

• Publication date

  2014-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/med.21300PMID 24002940
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PARP-1 and gene regulation: progress and puzzles.

  2013cited by this paper
• Vascular Smooth Muscle Cell Sirtuin 1 Protects Against DNA Damage and Inhibits Atherosclerosis

  2013cited by this paper
• Negative regulation of inflammation by SIRT1.

  2013cited by this paper
• PARP inhibitors: polypharmacology versus selective inhibition

  2013cited by this paper
• Crosstalk between poly(ADP-ribose) polymerase and sirtuin enzymes.

  2013cited by this paper
• Macrodomain-containing proteins are new mono-ADP-ribosylhydrolases

  2013cited by this paper
• A family of macrodomain proteins reverses cellular mono-ADP-ribosylation

  2013cited by this paper
• Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

  2013cited by this paper
• Poly (ADP‐ribose) polymerase inhibitor reduces heart ischaemia/reperfusion injury via inflammation and Akt signalling in rats

  2013cited by this paper
• Poly(ADP-ribose) polymerase 1 inhibition protects against low shear stress induced inflammation.

  2013cited by this paper
• Seven sirtuins for seven deadly diseases of aging.

  2013cited by this paper
• Poly(ADP-ribose) polymerase inhibition prevents reactive oxygen species induced inhibition of aldehyde dehydrogenase2 activity.

  2013cited by this paper
• Enhanced NF-κB Activity Impairs Vascular Function Through PARP-1–, SP-1–, and COX-2–Dependent Mechanisms in Type 2 Diabetes

  2013cited by this paper
• Deficiency of terminal ADP‐ribose protein glycohydrolase TARG1/C6orf130 in neurodegenerative disease

  2013cited by this paper
• Poly(ADP-ribose) polymerase-1-induced NAD(+) depletion promotes nuclear factor-κB transcriptional activity by preventing p65 de-acetylation.

  2013cited by this paper
• Poly (ADP-ribose) polymerase 14 and its enzyme activity regulates T(H)2 differentiation and allergic airway disease.

  2013cited by this paper
• Sirtuins as regulators of metabolism and healthspan

  2012cited by this paper
• Targeting Sirtuin 1 to Improve Metabolism: All You Need Is NAD+?

  2012cited by this paper
• LOX-1 in atherosclerosis: biological functions and pharmacological modifiers

  2012cited by this paper
• Quantitative proteomics profiling of the poly(ADP-ribose)-related response to genotoxic stress

  2012cited by this paper
• Poly(ADP-Ribose) Polymerase 1 Inhibition Improves Coronary Arteriole Function in Type 2 Diabetes Mellitus

  2012cited by this paper
• Sirtuin 1 and sirtuin 3: physiological modulators of metabolism.

  2012cited by this paper
• Inflammation in Atherosclerosis

  2012cited by this paper
• The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease.

  2012cited by this paper
• SIRT1: new avenues of discovery for disorders of oxidative stress

  2012cited by this paper
• Insulin resistance and atherosclerosis.

  2012cited by this paper
• Poly(ADP-ribose) polymerase-2: emerging transcriptional roles of a DNA-repair protein

  2012cited by this paper
• Role of poly(ADP‐ribose) polymerases in the regulation of inflammatory processes

  2012cited by this paper
• Poly(ADP-ribose) polymerase 1 inhibition protects human aortic endothelial cells against LPS-induced inflammation response.

  2012cited by this paper
• Inflammasome-activated caspase 7 cleaves PARP1 to enhance the expression of a subset of NF-κB target genes.

  2012cited by this paper
• Age-Associated Changes In Oxidative Stress and NAD+ Metabolism In Human Tissue

  2012cited by this paper
• Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors

  2012cited by this paper
• The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art.

  2012cited by this paper
• Identification of pim kinases as novel targets for PJ34 with confounding effects in PARP biology.

  2012cited by this paper
• Reanalysis of phosphoproteomics data uncovers ADP-ribosylation sites

  2012cited by this paper
• INHIBITION OF THE ACTIVITY OF POLY (ADP-RIBOSE) POLYMERASE REDUCES HEART ISCHAEMIA/REPERFUSION INJURY VIA SUPPRESSING JNK MEDIATED AIF TRANSLOCATION

  2012cited by this paper
• Structural Basis for DNA Damage–Dependent Poly(ADP-ribosyl)ation by Human PARP-1

  2012cited by this paper
• The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.

  2012cited by this paper
• Tanshinone II-A inhibits oxidized LDL-induced LOX-1 expression in macrophages by reducing intracellular superoxide radical generation and NF-κB activation.

  2012cited by this paper
• Mass spectrometry-based functional proteomics of poly(ADP-ribose) polymerase-1

  2011cited by this paper
• Cellular and cytokine-based inflammatory processes as novel therapeutic targets for the prevention and treatment of atherosclerosis.

  2011cited by this paper
• Poly(ADP-Ribose) (PAR) Binding to Apoptosis-Inducing Factor Is Critical for PAR Polymerase-1–Dependent Cell Death (Parthanatos)

  2011cited by this paper
• PARP inhibition in atherosclerosis and its effects on dendritic cells, T cells and auto-antibody levels

  2011cited by this paper
• Crosstalk between components of circadian and metabolic cycles in mammals.

  2011cited by this paper
• PARP-2 regulates SIRT1 expression and whole-body energy expenditure.

  2011cited by this paper
• PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation.

  2011cited by this paper
• Minocycline reduces plaque size in diet induced atherosclerosis via p27(Kip1).

  2011cited by this paper
• Opposing roles of PARP-1 in MMP-9 and TIMP-2 expression and mast cell degranulation in dyslipidemic dilated cardiomyopathy.

  2011cited by this paper
• iNOS induction and PARP-1 activation in human atherosclerotic lesions: an immunohistochemical and ultrastructural approach.

  2011cited by this paper
• POLY(ADP‐RIBOSE) POLYMERASE‐2 DEPLETION REDUCES DOXORUBICIN‐INDUCED DAMAGE THROUGH SIRT1 INDUCTION

  2011cited by this paper
• Poly(ADP-ribose) Polymerase 1 Is Indispensable for Transforming Growth Factor-β Induced Smad3 Activation in Vascular Smooth Muscle Cell

  2011cited by this paper
• Loss of Tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism.

  2011cited by this paper
• Matrix metalloproteinase inhibition with tetracyclines for the treatment of coronary artery disease.

  2011cited by this paper
• Effect of doxycycline on atherosclerosis: from bench to bedside.

  2011cited by this paper
• Glucagon-like peptide 1 protects microvascular endothelial cells by inactivating the PARP-1/iNOS/NO pathway.

  2011cited by this paper
• The role of mammalian sirtuins in the regulation of metabolism, aging, and longevity.

  2011cited by this paper
• Franklin H. Epstein Lecture: Sirtuins, aging, and medicine.

  2011cited by this paper
• The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment.

  2011cited by this paper
• Tanshinone II-A attenuates and stabilizes atherosclerotic plaques in apolipoprotein-E knockout mice fed a high cholesterol diet.

  2011cited by this paper
• Interference between PARPs and SIRT1: a novel approach to healthy ageing?

  2011cited by this paper
• Sirtuins at a glance

  2011cited by this paper
• The effect of doxycycline on atherogenesis in apoE-knockout mice.

  2011cited by this paper
• Non-antibacterial tetracyclines modulate mediators of periodontitis and atherosclerotic cardiovascular disease: a mechanistic link between local and systemic inflammation.

  2011cited by this paper
• The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy

  2011cited by this paper
• Age Related Changes in NAD+ Metabolism Oxidative Stress and Sirt1 Activity in Wistar Rats

  2011cited by this paper
• Genetic ablation of PARP-1 protects against oxazolone-induced contact hypersensitivity by modulating oxidative stress.

  2010cited by this paper
• Identification of the Aryl Hydrocarbon Receptor Target Gene TiPARP as a Mediator of Suppression of Hepatic Gluconeogenesis by 2,3,7,8-Tetrachlorodibenzo-p-dioxin and of Nicotinamide as a Corrective Agent for This Effect*

  2010cited by this paper
• SIRT1 Deacetylates and Inhibits SREBP-1C Activity in Regulation of Hepatic Lipid Metabolism*

  2010cited by this paper
• PARP-14 Functions as a Transcriptional Switch for Stat6-dependent Gene Activation*

  2010cited by this paper
• Mechanical stretch enhances NF-kappaB-dependent gene expression and poly(ADP-ribose) synthesis in synovial cells.

  2010cited by this paper
• SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis

  2010cited by this paper
• Toward a unified nomenclature for mammalian ADP-ribosyltransferases.

  2010cited by this paper
• Regulation of SIRT1 in cellular functions: role of polyphenols.

  2010cited by this paper
• Effect of an antimicrobial agent on atherosclerotic plaques: assessment of metalloproteinase activity by molecular imaging.

  2010cited by this paper
• Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP.

  2010cited by this paper
• Inflammatory and age-related pathologies in mice with ectopic expression of human PARP-1.

  2010cited by this paper
• PARP inhibition: PARP1 and beyond

  2010cited by this paper
• Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle.

  2010cited by this paper
• Serum or target deprivation‐induced neuronal death causes oxidative neuronal accumulation of Zn2+ and loss of NAD+

  2010cited by this paper
• Investigation of PARP-1, PARP-2, and PARG interactomes by affinity-purification mass spectrometry

  2010cited by this paper
• Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications.

  2010cited by this paper
• Poly(ADP-Ribose) Polymerase-1 Is a Determining Factor in Crm1-Mediated Nuclear Export and Retention of p65 NF-κB upon TLR4 Stimulation

  2010cited by this paper
• The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways.

  2010cited by this paper
• SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis

  2010cited by this paper
• Combining affinity purification by ADP-ribose-binding macro domains with mass spectrometry to define the mammalian ADP-ribosyl proteome

  2009cited by this paper
• Poly(ADP-ribose) polymerase 1 at the crossroad of metabolic stress and inflammation in aging

  2009cited by this paper
• Poly (ADP-ribose) Polymerase Inhibition Improves Endothelial Dysfunction Induced by Hyperhomocysteinemia in Rats

  2009cited by this paper
• Poly(ADP-Ribose) Polymerase Mediates Inflammation in a Mouse Model of Contact Hypersensitivity

  2009cited by this paper
• A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of th

  2009cited by this paper
• Pharmacotherapy of coronary atherosclerosis

  2009cited by this paper
• Reduced apoptosis and plaque necrosis in advanced atherosclerotic lesions of Apoe-/- and Ldlr-/- mice lacking CHOP.

  2009cited by this paper
• SIRT1 Promotes Cell Survival under Stress by Deacetylation-Dependent Deactivation of Poly(ADP-Ribose) Polymerase 1

  2009cited by this paper
• AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity

  2009cited by this paper
• Poly(ADP-ribose) polymerase mediates inflammation in a mouse model of contact hypersensitivity.

  2009cited by this paper
• Protective Effects of PARP-1 Knockout on Dyslipidemia-Induced Autonomic and Vascular Dysfunction in ApoE−/− Mice: Effects on eNOS and Oxidative Stress

  2009cited by this paper
• Inhibition of matrix metalloproteinase-2 by PARP inhibitors.

  2009cited by this paper
• Thieno[2,3-c]Isoquinolin-5-one, a Potent Poly(ADP-Ribose) Polymerase Inhibitor, Promotes Atherosclerotic Plaque Regression in High-Fat Diet-Fed Apolipoprotein E-Deficient Mice: Effects on Inflammatory Markers and Lipid Content

  2009cited by this paper
• Nicotinamide Prevents NAD+ Depletion and Protects Neurons Against Excitotoxicity and Cerebral Ischemia: NAD+ Consumption by SIRT1 may Endanger Energetically Compromised Neurons

  2009cited by this paper
• Poly (ADP-Ribose) polymerase inhibition attenuates atherosclerotic plaque development in ApoE-/- mice with hyperhomocysteinemia.

  2009cited by this paper
• Molecular mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites

  2009cited by this paper

• Platelet-rich plasma-derived extracellular vesicles delivered niraparib for ultrasound imaging and atherosclerosis treatment.

  2026cites this paper
• Poly(ADP-ribose) polymerase (PARP) inhibitors in cardiovascular, and cerebrovascular diseases: mechanisms, current trends and challenge for clinical translation.

  2026cites this paper
• Nicotinamide N-methyltransferase in cardiovascular Diseases: Mechanistic insights and therapeutic potential.

  2025cites this paper
• "Yin-Yang" of PARP1 in genotoxic and inflammatory response.

  2025cites this paper
• PARP1 contributes to intimal hyperplasia by regulating METTL3-mediated m6A methylation of TRAIL

  2025cites this paper
• SRY mediates male-specific susceptibility to acute liver injury

  2025cites this paper
• NAD+ metabolism and therapeutic strategies in cardiovascular diseases

  2024cites this paper
• NAD+ depletion is central to placental dysfunction in an inflammatory subclass of preeclampsia

  2024cites this paper
• Oxidative stress and PARP activation in the lungs is an early event in COVID-19 pneumonia

  2024cites this paper
• Evaluation of serum salusin-α and β levels in patients with obstructive sleep apnea.

  2024cites this paper
• TRIM25-mediated XRCC1 ubiquitination accelerates atherosclerosis by inducing macrophage M1 polarization and programmed death

  2024cites this paper
• PARP1 Promotes Heart Regeneration and Cardiomyocyte Proliferation

  2024cites this paper
• Stachydrine, a potential drug for the treatment of cardiovascular system and central nervous system diseases.

  2023cites this paper
• Sirtuins in macrophage immune metabolism: A novel target for cardiovascular disorders.

  2023cites this paper
• DNA damage response, a double-edged sword for vascular aging.

  2023cites this paper
• NAD+ depletion and altered mitochondrial function are key to the establishment of placental dysfunction in an inflammatory-driven subclass of preeclampsia

  2023cites this paper
• Macrophage death in atherosclerosis: potential role in calcification

  2023cites this paper
• PARP-1 inhibitor alleviates liver lipid accumulation of atherosclerosis via modulating bile acid metabolism and gut microbes.

  2023cites this paper
• NAD+ Homeostasis and NAD+-Consuming Enzymes: Implications for Vascular Health

  2023cites this paper
• Inhibition of the DNA Damage Response Attenuates Ectopic Calcification in Pseudoxanthoma Elasticum.

  2022cites this paper
• Design, synthesis, and biological evaluation of novel NO‐releasing 4‐chromanone derivatives as potential vasodilator agents

  2022cites this paper
• Recent advances in structural types and medicinal chemistry of PARP-1 inhibitors

  2022cites this paper
• Sirtuin 3 Dependent and Independent Effects of NAD+ to Suppress Vascular Inflammation and Improve Endothelial Function in Mice

  2022cites this paper
• NRP2 promotes atherosclerosis by upregulating PARP1 expression and enhancing low shear stress‐induced endothelial cell apoptosis

  2022cites this paper
• Corilagin Reduces Resistance to PARP Inhibitors by Inhibiting the ERK Signaling Pathway in Ovarian Cancers

  2021cites this paper
• Roles of Macrophages in Atherogenesis

  2021cites this paper
• Therapeutic Potential of Emerging NAD+-Increasing Strategies for Cardiovascular Diseases

  2021cites this paper
• Deacetylation-dependent regulation of PARP1 by SIRT2 dictates ubiquitination of PARP1 in oxidative stress-induced vascular injury

  2021cites this paper
• PARPs in lipid metabolism and related diseases.

  2021cites this paper
• Elevated Expression of MiR-17 in Microglia of Alzheimer’s Disease Patients Abrogates Autophagy-Mediated Amyloid-β Degradation

  2021influential citation
• YY-11, a camel milk-derived peptide, inhibits TGF-β-mediated atherogenic signaling in human vascular smooth muscle cells.

  2021cites this paper
• NAD+ deficiency and mitochondrial dysfunction in granulosa cells of women with polycystic ovary syndrome

  2021cites this paper
• Sp1 Targeted PARP1 Inhibition Protects Cardiomyocytes From Myocardial Ischemia–Reperfusion Injury via Downregulation of Autophagy

  2021cites this paper
• Different types of cell death in vascular diseases

  2021cites this paper
• Systematic comparison of ligand-based and structure-based virtual screening methods on poly (ADP-ribose) polymerase-1 inhibitors

  2021cites this paper
• Poly(ADP-Ribose) Polymerase Activity and Coronary Artery Disease in Type 2 Diabetes Mellitus

  2020cites this paper
• The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy-Current progress and future direction.

  2020cites this paper
• Antioxidants

  2020cites this paper
• Sobriety and Satiety: Is NAD+ the Answer?

  2020cites this paper
• Investigation of the three-dimensional structure and interaction mechanism of poly (ADP-ribose) polymerase 4

  2020cites this paper
• The E3 ubiquitin ligase Smurf2 regulates PARP1 stability to alleviate oxidative stress‐induced injury in human umbilical vein endothelial cells

  2020cites this paper
• SIRT3 inhibits cardiac hypertrophy by regulating PARP-1 activity

  2020cites this paper
• The poly(ADP-ribosyl)ation of BRD4 mediated by PARP1 promoted pathological cardiac hypertrophy

  2020cites this paper
• Therapeutic potential of blood flow mimetic compounds in preventing endothelial dysfunction and atherosclerosis.

  2020cites this paper
• Association study of hsa_circ_0001946, hsa-miR-7-5p and PARP1 in coronary atherosclerotic heart disease.

  2020cites this paper
• E3 Ubiquitin ligase NEDD4 family‑regulatory network in cardiovascular disease

  2020cites this paper
• The role of ADP-ribose metabolism in metabolic regulation, adipose tissue differentiation, and metabolism

  2020cites this paper
• The Role of PARPs in Inflammation—And Metabolic—Related Diseases: Molecular Mechanisms and Beyond

  2019cites this paper
• Danhong injection in cardiovascular and cerebrovascular diseases: Pharmacological actions, molecular mechanisms, and therapeutic potential.

  2019cites this paper
• Targeting epigenetics and non-coding RNAs in atherosclerosis: from mechanisms to therapeutics.

  2019cites this paper
• Rutaecarpine: A promising cardiovascular protective alkaloid from Evodia rutaecarpa (Wu Zhu Yu).

  2019cites this paper
• A simple protocol for isolating mouse lung endothelial cells

  2019cites this paper
• Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics

  2019influential citation
• Macrophage Death as a Pharmacological Target in Atherosclerosis

  2019cites this paper
• Deoxyribonucleic acid damage gene expression, ligase activity and correlation with coronary atherosclerotic plaque morphology.

  2019cites this paper
• Salvia miltiorrhiza in Treating Cardiovascular Diseases: A Review on Its Pharmacological and Clinical Applications

  2019cites this paper
• Novel Treatment Strategies for the Nervous System: Circadian Clock Genes, Non-coding RNAs, and Forkhead Transcription Factors.

  2018cites this paper
• Atheroprotective Effects and Molecular Targets of Tanshinones Derived From Herbal Medicine Danshen

  2018cites this paper
• Flow-dependent epigenetic regulation of IGFBP5 expression by H3K27me3 contributes to endothelial anti-inflammatory effects

  2018cites this paper
• Salvia miltiorrhizaBurge (Danshen): a golden herbal medicine in cardiovascular therapeutics

  2018cites this paper
• PARP-1 Involvement in Autophagy and Their Roles in Apoptosis of Vascular Smooth Muscle Cells under Oxidative Stress.

  2018cites this paper
• Targeting LOX‐1 in atherosclerosis and vasculopathy: current knowledge and future perspectives

  2018cites this paper
• PARP1 promote autophagy in cardiomyocytes via modulating FoxO3a transcription

  2018cites this paper
• Tanshinone IIA attenuates TNF-α induced PTX3 expression and monocyte adhesion to endothelial cells through the p38/NF-κB pathway.

  2018cites this paper
• PARP-1 inhibition attenuates cardiac fibrosis induced by myocardial infarction through regulating autophagy.

  2018cites this paper
• Poly(ADP-ribosyl)ated PXR is a critical regulator of acetaminophen-induced hepatotoxicity

  2018cites this paper
• Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders

  2018cites this paper
• The mechanistic target of rapamycin (mTOR) and the silent mating-type information regulation 2 homolog 1 (SIRT1): oversight for neurodegenerative disorders.

  2018cites this paper
• Oxidative Stress and Vascular Diseases: Effect of Physical Exercise

  2018cites this paper
• Septin4 as a novel binding partner of PARP1 contributes to oxidative stress induced human umbilical vein endothelial cells injure.

  2018cites this paper
• Dysregulation of PARP1 is involved in development of Barrett’s esophagus

  2018cites this paper
• Chrysophanol protects against doxorubicin-induced cardiotoxicity by suppressing cellular PARylation

  2018cites this paper
• Icariin, an Anti-atherosclerotic Drug from Chinese Medicinal Herb Horny Goat Weed

  2017cites this paper
• Regulatory Roles of PARP-1 and Lipids in Epigenetic Mechanisms

  2017cites this paper
• Harnessing the Power of SIRT1 and Non-coding RNAs in Vascular Disease.

  2017cites this paper
• Targeting vascular (endothelial) dysfunction

  2017cites this paper
• PARP-1 Variant Rs1136410 Confers Protection against Coronary Artery Disease in a Chinese Han Population: A Two-Stage Case-Control Study Involving 5643 Subjects

  2017cites this paper
• Suberanilohydroxamic Acid as a Pharmacological Kruppel‐Like Factor 2 Activator That Represses Vascular Inflammation and Atherosclerosis

  2017cites this paper
• Novel PARP-1 Inhibitor Scaffolds Disclosed by a Dynamic Structure-Based Pharmacophore Approach

  2017cites this paper
• Synthesis of the novel PARP-1 inhibitor AG-690/11026014 and its protective effects on angiotensin II-induced mouse cardiac remodeling

  2017cites this paper
• Regeneration in the nervous system with erythropoietin.

  2016cites this paper
• Poly(ADP-ribose) Polymerase 1 Represses Liver X Receptor-mediated ABCA1 Expression and Cholesterol Efflux in Macrophages*

  2016cites this paper
• Atheroprotective laminar flow inhibits Hippo pathway effector YAP in endothelial cells.

  2016cites this paper
• Regeneration in the nervous system with erythropoietin.

  2016cites this paper
• SIRT6 protects against endothelial dysfunction and atherosclerosis in mice

  2016cites this paper
• Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer

  2016cites this paper
• SIRT1 improves VSMC functions in atherosclerosis.

  2016cites this paper
• PECAM1 regulates flow-mediated Gab1 tyrosine phosphorylation and signaling.

  2016cites this paper
• Association of Radiation-Induced Genes with Noncancer Chronic Diseases in Mayak Workers Occupationally Exposed to Prolonged Radiation

  2015cites this paper
• Integrative analysis of ocular complications in atherosclerosis unveils pathway convergence and crosstalk

  2015cites this paper
• The role of DNA damage and repair in atherosclerosis: A review.

  2015cites this paper
• Deletion of PARP-2 induces hepatic cholesterol accumulation and decrease in HDL levels.

  2014cites this paper
• PARP-1 activation causes neuronal death in the hippocampal CA1 region by increasing the expression of Ca(2+)-permeable AMPA receptors.

  2014cites this paper
• Targeting hydrogen sulfide as a promising therapeutic strategy for atherosclerosis.

  2014cites this paper
• Smoking and atherosclerosis: mechanisms of disease and new therapeutic approaches.

  2014cites this paper
• Effectiveness of combination therapy of atorvastatin and non lipid-modifying tanshinone IIA from Danshen in a mouse model of atherosclerosis.

  2014cites this paper